Cboe AU - Free Realtime Quote AUD

Nova Eye Medical Limited (EYE.XA)

0.2800 +0.0500 (+21.74%)
As of 1:51 PM GMT+10. Market Open.
Loading Chart for EYE.XA
DELL
  • Previous Close 0.2300
  • Open 0.2750
  • Bid 0.2750 x --
  • Ask 0.2800 x --
  • Day's Range 0.2650 - 0.2900
  • 52 Week Range 0.1100 - 0.3250
  • Volume 425,413
  • Avg. Volume 149,271
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Feb 23, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

www.nova-eye.com

--

Full Time Employees

June 30

Fiscal Year Ends

--

Sector

--

Industry

Recent News: EYE.XA

Performance Overview: EYE.XA

Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EYE.XA
14.29%
MSCI WORLD
9.57%

1-Year Return

EYE.XA
24.44%
MSCI WORLD
22.15%

3-Year Return

EYE.XA
13.85%
MSCI WORLD
19.29%

5-Year Return

EYE.XA
0.00%
MSCI WORLD
0.00%

Compare To: EYE.XA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EYE.XA

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -76.24%

  • Return on Assets (ttm)

    -23.09%

  • Return on Equity (ttm)

    -68.36%

  • Revenue (ttm)

    18.77M

  • Net Income Avi to Common (ttm)

    -14.31M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.61M

  • Total Debt/Equity (mrq)

    7.14%

  • Levered Free Cash Flow (ttm)

    -1.25M

Research Analysis: EYE.XA

Company Insights: EYE.XA

Research Reports: EYE.XA